Onkologie. 2025:19(5):306-311 | DOI: 10.36290/xon.2025.055

Pemigatinib in the treatment of metastatic intrahepatic cholangiocellular carcinoma with FGFR2 alteration

Martin Palkovský1, 2, Marián Liberko1, 2, Renata Soumarová1, 2
1 Onkologická klinika, 3. LF UK a FNKV, Praha
2 3. lékařská fakulta Univerzity Karlovy, Praha

Pemigatanib is a selective FGFR2 inhibitor for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with fusion or rearrangement of fibroblast growth factor receptor 2 (fibroblast growth factor receptor 2, FGFR2) who have progressed after at least one prior line of systemic therapy. This case report documents the atypical behavior of cholangiocellular carcinoma diagnosed in 2013 at clinical stage II. After progression on first-line treatment (FOLFOX), treatment with pemigatinib was initiated in June 2024 and continues to date.

Keywords: cholangiocellular carcinoma, FGFR2, targeted therapy, pemigatinib.

Accepted: November 25, 2025; Published: December 15, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Palkovský M, Liberko M, Soumarová R. Pemigatinib in the treatment of metastatic intrahepatic cholangiocellular carcinoma with FGFR2 alteration. Onkologie. 2025;19(5):306-311. doi: 10.36290/xon.2025.055.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 15.12.2026

    References

    1. de Groen PC, Gores GJ, LaRusso NF, et al. Biliary tract cancers. N Engl J Med 1999;341:1368-1378. doi: 10.1056/NEJM199910283411807. Go to original source... Go to PubMed...
    2. Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10391):1853-1865. doi: 10.1016/S0140-6736(23)00727-4. Go to original source... Go to PubMed...
    3. Burris HA 3rd, Okusaka T, Vogel A, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial Lancet Oncol. 2024;25(5):626-635. doi: 10.1016/S1470-2045(24)00082-2. PMID: 38697156. Go to original source... Go to PubMed...
    4. Graham RP, Barr Fritcher EG, Pestova E, et al. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum Pathol. 2014;45:1630-1638. doi: 10.1016/j.humpath.2014.03.014. Go to original source... Go to PubMed...
    5. Ross JS, Wang K, Gay L, et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist. 2014; 19:235-242. doi: 10.1634/theoncologist.2013-0352. Go to original source... Go to PubMed...
    6. Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671-684. doi: 10.1016/S1470-2045(20)30109-1. Go to original source... Go to PubMed...
    7. Vogel A, Sahai V, Hollebecque A, et al. O-2 Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: final results from FIGHT-202. Ann Oncol. 2022;33(suppl 4):S379. doi: 10.1016/S1470-2045(20)30109-1. Go to original source... Go to PubMed...
    8. Buckarma E, De La Cruz G, Truty M, et al. Impact of FGFR2 gene fusions on survival of patients with intrahepatic cholangiocarcinoma following curative intent resection. HPB (Oxford). 2022;24(10):1748-1756. doi: 10.1016/j.hpb.2022.05.1341. Go to original source... Go to PubMed...
    9. Matikas A, Mistriotis D, Georgoulias V, et al. Current and future approaches in the management of non-small-cell lung cancer patients with resistance to EGFR TKIs. Clin Lung Cancer. 2015;16:252-261. doi: 10.1016/j.cllc.2014.12.013. Go to original source... Go to PubMed...
    10. Rusthoven CG, Yeh N, Gaspar LE. Radiation therapy for oligometastatic non-small cell lung cancer: theory and practice. Cancer J. 2015;21:404-412. doi: 10.1097/PPO. 0000000000000143. Go to original source... Go to PubMed...
    11. Sindhu KK, Leiter A, Moshier E, et al. Durable disease control with local treatment for oligoprogression of metastatic solid tumors treated with immune checkpoint blockade. Cancer Treat. Res. Commun. 2020;25:100216. doi: 10.1016/j.ctarc.2020.100216. Go to original source... Go to PubMed...
    12. Simone CB 2nd, Burri SH, Heinzerling JH. Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies. Transl Lung Cancer Res. 2015;4:545-552. doi: 10.3978/j.issn.2218-6751.2015.10.05. Go to original source... Go to PubMed...
    13. Ettinger DS, Wood DE, Akerley W, et al. Non-small cell lung cancer, version 6.2015. J Natl Compr Canc Netw. 2015;13:515-524. doi: 10.6004/jnccn.2015.0071. Go to original source... Go to PubMed...
    14. Gridelli C, de Marinis F, Cappuzzo F, et al. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. Clin Lung Can­cer. 2014;15:173-81. doi: 10.1016/j.cllc.2013.12.002. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.